All Blogs

Sep 12, 2022

Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...

Sep 09, 2022

Treatment for pancreatic cancer patients is challenging and not well defined, especially for patients with disease progression or adverse events seen after initial treatment. Studies suggest that, after diagnosis, about 22% of pancreatic cancer patients, regardless of their clinical stage of cancer, receive no trea...

Sep 09, 2022

Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the alopecia areata treatment market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of alopecia areata treatment options are available. The main goal of treatment is...

Sep 08, 2022

eCential Robotics Receives FDA Clearance for its Surgical Robotic Platform for Spine Surgery The FDA has approved a robotic spinal surgery platform designed to assist human surgeons by automating several steps of spinal procedures. The platform, developed by eCential Robotics, combines intraoperative 2D and 3D i...

Sep 07, 2022

Over the past few years, there has been a massive advancement and adoption in the digital health segment. The segment is likely to exhibit growth and onward trend in the coming years as well, owing to the huge capital investment and positive approach by the healthcare authorities Similar, some key factors, such as ...

Sep 06, 2022

FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...

Sep 05, 2022

WHIM Syndrome possessing limited cures paves the way toward evolving demand for novel treatment therapies. Moreover, the increasing prevalence and R&D activities drive the WHIM syndrome treatment market forward. As per DelveInsight’s latest WHIM Syndrome epidemiology report, there were approximately 180 diag...

Sep 02, 2022

There are a few major unmet needs in the primary sclerosing cholangitis (PSC) treatment market, which include a lack of effective therapies, proven surveillance strategies, tools for early detection of malignancies, impact on quality of life (QoL), and surrogate endpoints in primary sclerosing cholangitis clinical ...

Sep 01, 2022

FDA Approved IDE for Picso® Pivotal Study of Miracor Medical On August 23, 2022, Miracor Medical SA, a provider of innovative solutions for the treatment of severe cardiac diseases, announced that the FDA has approved an Investigational Device Exemption (IDE), allowing the company to begin a pivotal study with i...

Aug 31, 2022

The rapid growth in technology and innovation are bringing new opportunities and scope for simplification in product development and process and are creating comfort and simplifying lives in their own way. The ongoing breakthroughs and innovation are leading to better outcomes/productivity, saving time, increasing ...